Philippe Armand

36.1k total citations · 10 hit papers
334 papers, 17.5k citations indexed

About

Philippe Armand is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Philippe Armand has authored 334 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 165 papers in Oncology, 148 papers in Pathology and Forensic Medicine and 126 papers in Hematology. Recurrent topics in Philippe Armand's work include Lymphoma Diagnosis and Treatment (145 papers), Hematopoietic Stem Cell Transplantation (93 papers) and CAR-T cell therapy research (75 papers). Philippe Armand is often cited by papers focused on Lymphoma Diagnosis and Treatment (145 papers), Hematopoietic Stem Cell Transplantation (93 papers) and CAR-T cell therapy research (75 papers). Philippe Armand collaborates with scholars based in United States, Canada and Italy. Philippe Armand's co-authors include Joseph H. Antin, Margaret A. Shipp, Robert J. Soiffer, Edwin P. Alyea, Haesook T. Kim, Corey Cutler, Vincent T. Ho, John Koreth, Scott J. Rodig and Stephen M. Ansell and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Philippe Armand

324 papers receiving 17.3k citations

Hit Papers

PD-1 Blockade with Nivolumab in Relapsed or Refractory Ho... 2011 2026 2016 2021 2014 2011 2017 2014 2016 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    2014 2.7k citations Stephen M. Ansell, Gordon J. Freeman et al. profile →
  2. Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
    2011 809 citations John Koreth, Haesook T. Kim et al. profile →
  3. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
    2017 694 citations Robert Chen, Pier Luigi Zinzani et al. Journal of Clinical Oncology profile →
  4. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
    2014 611 citations Philippe Armand, Haesook T. Kim et al. Blood profile →
  5. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
    2016 555 citations Robert Redd, Gordon J. Freeman et al. Journal of Clinical Oncology profile →
  6. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
    2016 477 citations Philippe Armand, Margaret A. Shipp et al. Journal of Clinical Oncology profile →
  7. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
    2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
  8. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
    2017 339 citations Lakshmi Nayak, Ann S. LaCasce et al. Blood profile →
  9. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
    2016 305 citations Stephen M. Ansell, Philippe Armand et al. Blood profile →
  10. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation
    2014 286 citations Philippe Armand, Robert J. Soiffer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Armand United States 60 8.8k 6.4k 5.9k 5.0k 3.0k 334 17.5k
David C. Linch United Kingdom 74 7.0k 0.8× 3.7k 0.6× 6.6k 1.1× 8.9k 1.8× 4.9k 1.6× 358 20.9k
Gianluca Gaïdano Italy 73 9.4k 1.1× 4.5k 0.7× 11.0k 1.9× 2.9k 0.6× 7.7k 2.6× 616 20.4k
Oliver W. Press United States 70 7.7k 0.9× 3.4k 0.5× 7.0k 1.2× 1.6k 0.3× 2.5k 0.8× 388 17.9k
Ranjana H. Advani United States 66 10.2k 1.2× 4.6k 0.7× 13.5k 2.3× 1.8k 0.4× 5.5k 1.8× 456 20.0k
Wyndham H. Wilson United States 66 9.0k 1.0× 4.8k 0.8× 8.2k 1.4× 1.2k 0.2× 4.8k 1.6× 329 17.6k
H. Miles Prince Australia 59 5.8k 0.7× 3.2k 0.5× 4.2k 0.7× 4.2k 0.8× 1.7k 0.6× 428 14.8k
David G. Maloney United States 85 15.0k 1.7× 8.0k 1.3× 7.1k 1.2× 11.3k 2.3× 5.1k 1.7× 499 30.0k
Kensei Tobinai Japan 49 5.8k 0.7× 5.0k 0.8× 7.3k 1.2× 1.2k 0.2× 2.4k 0.8× 425 13.7k
Stephen M. Ansell United States 83 15.0k 1.7× 8.8k 1.4× 13.8k 2.3× 2.9k 0.6× 5.6k 1.9× 741 26.6k
Jürgen Finke Germany 58 3.8k 0.4× 3.4k 0.5× 2.6k 0.4× 6.9k 1.4× 2.7k 0.9× 396 12.9k

Countries citing papers authored by Philippe Armand

Since Specialization
Citations

This map shows the geographic impact of Philippe Armand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Armand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Armand more than expected).

Fields of papers citing papers by Philippe Armand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Armand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Armand. The network helps show where Philippe Armand may publish in the future.

Co-authorship network of co-authors of Philippe Armand

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Armand. A scholar is included among the top collaborators of Philippe Armand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Armand. Philippe Armand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nayak, Lakshmi, Ugonma Chukwueke, Christopher Meehan, et al.. (2024). A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).. Journal of Clinical Oncology. 42(16_suppl). 2006–2006. 9 indexed citations
2.
Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations
3.
4.
Timmerman, John M., David Lavie, Gareth P. Gregory, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7055–7055. 2 indexed citations
5.
Bu, Xia, Vikram R. Juneja, Carol Reynolds, et al.. (2021). Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research. 9(12). 1465–1475. 11 indexed citations
6.
Houot, Roch, Ronald Levy, Guillaume Cartron, & Philippe Armand. (2020). Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. European Journal of Cancer. 136. 4–6. 45 indexed citations
7.
Frigault, Matthew J., Jörg Dietrich, María Martínez-Lage, et al.. (2019). Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 134(11). 860–866. 160 indexed citations
8.
Kim, Haesook T., Lindsey E. Roeker, Corey Cutler, et al.. (2019). Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 26(3). 529–539. 16 indexed citations
9.
Armand, Philippe, Andreas Engert, Anas Younes, et al.. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. Journal of Clinical Oncology. 36(14). 1428–1439. 455 indexed citations breakdown →
10.
Cader, Fathima Zumla, Ron C.J. Schackmann, Xihao Hu, et al.. (2018). Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood. 132(8). 825–836. 111 indexed citations
11.
Epperla, Narendranath, Kwang Woo Ahn, Philippe Armand, et al.. (2017). Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation. 24(1). 78–85. 7 indexed citations
12.
Lampson, Benjamin L., Haesook T. Kim, Matthew S. Davids, et al.. (2017). Efficacy Results of a Phase 2 Trial Evaluating Idelalisib Plus Ofatumumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia. Blood. 130. 1734–1734. 4 indexed citations
13.
Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132. 694 indexed citations breakdown →
14.
Lampson, Benjamin L., Siddha Kasar, Tiago R. Matos, et al.. (2016). Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 128(2). 195–203. 227 indexed citations
15.
Koreth, John, Kristen E. Stevenson, Haesook T. Kim, et al.. (2012). Bortezomib-Based Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Transplantation. Journal of Clinical Oncology. 30(26). 3202–3208. 104 indexed citations
16.
Amrein, Philip C., Eyal C. Attar, Tak Takvorian, et al.. (2011). Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 17(9). 2977–2986. 100 indexed citations
17.
Cutler, Corey, Haesook T. Kim, Gary Bradwin, et al.. (2010). Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury. Biology of Blood and Marrow Transplantation. 16(8). 1180–1185. 60 indexed citations
18.
Armand, Philippe, Haesook T. Kim, Corey Cutler, et al.. (2008). Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology. 26(35). 5767–5774. 80 indexed citations
19.
Armand, Philippe, Haesook T. Kim, Corey Cutler, et al.. (2007). Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 109(10). 4586–4588. 318 indexed citations
20.
Armand, Philippe, A C Knapp, Alec J. Hirsch, Eric Wieschaus, & Michael D. Cole. (1994). A novel basic helix-loop-helix protein is expressed in muscle attachment sites of the Drosophila epidermis.. Molecular and Cellular Biology. 14(6). 4145–4154. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David C. Linch Breakdown of academic impact, for papers by Gianluca Gaïdano Breakdown of academic impact, for papers by Oliver W. Press Breakdown of academic impact, for papers by Ranjana H. Advani Breakdown of academic impact, for papers by Wyndham H. Wilson Breakdown of academic impact, for papers by H. Miles Prince Breakdown of academic impact, for papers by David G. Maloney Breakdown of academic impact, for papers by Kensei Tobinai Breakdown of academic impact, for papers by Stephen M. Ansell Breakdown of academic impact, for papers by Jürgen Finke
Rankless by CCL
2026